These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 20634067

  • 1. Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists.
    Kiyoi T, York M, Francis S, Edwards D, Walker G, Houghton AK, Cottney JE, Baker J, Adam JM.
    Bioorg Med Chem Lett; 2010 Aug 15; 20(16):4918-21. PubMed ID: 20634067
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.
    Moir EM, Yoshiizumi K, Cairns J, Cowley P, Ferguson M, Jeremiah F, Kiyoi T, Morphy R, Tierney J, Wishart G, York M, Baker J, Cottney JE, Houghton AK, McPhail P, Osprey A, Walker G, Adam JM.
    Bioorg Med Chem Lett; 2010 Dec 15; 20(24):7327-30. PubMed ID: 21074434
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, and structure-activity relationships of indole-3-heterocycles as agonists of the CB1 receptor.
    Morrison AJ, Adam JM, Baker JA, Campbell RA, Clark JK, Cottney JE, Deehan M, Easson AM, Fields R, Francis S, Jeremiah F, Keddie N, Kiyoi T, McArthur DR, Meyer K, Ratcliffe PD, Schulz J, Wishart G, Yoshiizumi K.
    Bioorg Med Chem Lett; 2011 Jan 01; 21(1):506-9. PubMed ID: 21075630
    [Abstract] [Full Text] [Related]

  • 4. The discovery of novel indole-2-carboxamides as cannabinoid CB(1) receptor antagonists.
    Cowley PM, Baker J, Barn DR, Buchanan KI, Carlyle I, Clark JK, Clarkson TR, Deehan M, Edwards D, Goodwin RR, Jaap D, Kiyoi Y, Mort C, Palin R, Prosser A, Walker G, Ward N, Wishart G, Young T.
    Bioorg Med Chem Lett; 2011 Jan 01; 21(1):497-501. PubMed ID: 21075628
    [Abstract] [Full Text] [Related]

  • 5. Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators.
    Nguyen T, German N, Decker AM, Li JX, Wiley JL, Thomas BF, Kenakin TP, Zhang Y.
    Bioorg Med Chem; 2015 May 01; 23(9):2195-2203. PubMed ID: 25797163
    [Abstract] [Full Text] [Related]

  • 6. Indole-2-carboxamides as allosteric modulators of the cannabinoid CB₁ receptor.
    Piscitelli F, Ligresti A, La Regina G, Coluccia A, Morera L, Allarà M, Novellino E, Di Marzo V, Silvestri R.
    J Med Chem; 2012 Jun 14; 55(11):5627-31. PubMed ID: 22571451
    [Abstract] [Full Text] [Related]

  • 7. Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
    Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Yao BB, Hsieh GC, Pai M, Zhu CZ, Chandran P, Meyer MD.
    J Med Chem; 2010 Jan 14; 53(1):295-315. PubMed ID: 19921781
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.
    Kopka IE, Lin LS, Jewell JP, Lanza TJ, Fong TM, Shen CP, Lao ZJ, Ha S, Castonguay LG, Van der Ploeg L, Goulet MT, Hagmann WK.
    Bioorg Med Chem Lett; 2010 Aug 15; 20(16):4757-61. PubMed ID: 20643546
    [Abstract] [Full Text] [Related]

  • 9. Identification and hit-to-lead optimization of a novel class of CB1 antagonists.
    Letourneau JJ, Jokiel P, Olson J, Riviello CM, Ho KK, McAleer L, Yang J, Swanson RN, Baker J, Cowley P, Edwards D, Ward N, Ohlmeyer MH, Webb ML.
    Bioorg Med Chem Lett; 2010 Sep 15; 20(18):5449-53. PubMed ID: 20719511
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor.
    Moloney GP, Angus JA, Robertson AD, Stoermer MJ, Robinson M, Wright CE, McRae K, Christopoulos A.
    Eur J Med Chem; 2008 Mar 15; 43(3):513-39. PubMed ID: 17582659
    [Abstract] [Full Text] [Related]

  • 11. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor.
    Deng H, Gifford AN, Zvonok AM, Cui G, Li X, Fan P, Deschamps JR, Flippen-Anderson JL, Gatley SJ, Makriyannis A.
    J Med Chem; 2005 Oct 06; 48(20):6386-92. PubMed ID: 16190764
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.
    Ratcliffe P, Adam JM, Baker J, Bursi R, Campbell R, Clark JK, Cottney JE, Deehan M, Easson AM, Ecker D, Edwards D, Epemolu O, Evans L, Fields R, Francis S, Harradine P, Jeremiah F, Kiyoi T, McArthur D, Morrison A, Passier P, Pick J, Schnabel PG, Schulz J, Steinbrede H, Walker G, Westwood P, Wishart G, Udo de Haes J.
    Bioorg Med Chem Lett; 2011 Apr 15; 21(8):2541-6. PubMed ID: 21411321
    [Abstract] [Full Text] [Related]

  • 13. Exploring SAR features in diverse library of 4-cyanomethyl-pyrazole-3-carboxamides suitable for further elaborations as CB1 antagonists.
    Cooper M, Receveur JM, Bjurling E, Nørregaard PK, Nielsen PA, Sköld N, Högberg T.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):26-30. PubMed ID: 19954978
    [Abstract] [Full Text] [Related]

  • 14. 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.
    Huffman JW, Szklennik PV, Almond A, Bushell K, Selley DE, He H, Cassidy MP, Wiley JL, Martin BR.
    Bioorg Med Chem Lett; 2005 Sep 15; 15(18):4110-3. PubMed ID: 16005223
    [Abstract] [Full Text] [Related]

  • 15. Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.
    Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Miller LN, Li L, Yao BB, Hsieh GC, Pai M, Zhu CZ, Chandran P, Meyer MD.
    J Med Chem; 2008 Mar 27; 51(6):1904-12. PubMed ID: 18311894
    [Abstract] [Full Text] [Related]

  • 16. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
    Manley PJ, Zartman A, Paone DV, Burgey CS, Henze DA, Della Penna K, Desai R, Leitl MD, Lemaire W, White RB, Yeh S, Urban MO, Kane SA, Hartman GD, Bilodeau MT, Trotter BW.
    Bioorg Med Chem Lett; 2011 Apr 15; 21(8):2359-64. PubMed ID: 21420857
    [Abstract] [Full Text] [Related]

  • 17. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity.
    Melvin LS, Milne GM, Johnson MR, Wilken GH, Howlett AC.
    Drug Des Discov; 1995 Nov 15; 13(2):155-66. PubMed ID: 8872458
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
    Seo HJ, Kim MJ, Lee SH, Lee SH, Jung ME, Kim MS, Ahn K, Kim J, Lee J.
    Bioorg Med Chem; 2010 Feb 15; 18(3):1149-62. PubMed ID: 20045337
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
    Cowley PM, Baker J, Buchanan KI, Carlyle I, Clark JK, Clarkson TR, Deehan M, Edwards D, Kiyoi Y, Martin I, Osbourn D, Walker G, Ward N, Wishart G.
    Bioorg Med Chem Lett; 2011 Apr 01; 21(7):2034-9. PubMed ID: 21334892
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists.
    Pasquini S, Mugnaini C, Ligresti A, Tafi A, Brogi S, Falciani C, Pedani V, Pesco N, Guida F, Luongo L, Varani K, Borea PA, Maione S, Di Marzo V, Corelli F.
    J Med Chem; 2012 Jun 14; 55(11):5391-402. PubMed ID: 22548457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.